Your session is about to expire
← Back to Search
Cisplatin for Lung Cancer
Study Summary
This trial is a Phase I study, which is the first step in testing a new cancer treatment. The goal is to find the highest dose of the new treatment that can be given without causing too much harm.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 45 Patients • NCT02000531Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My blood counts and liver/kidney functions are within normal ranges.My cancer has a visible tumor between 1.2 cm and 5 cm wide.A heart and lung surgeon agrees I can likely have surgery and that a specific cancer drug won't make surgery harder.My lung cancer diagnosis was confirmed by a quick test during my procedure.My lung cancer is in the early or middle stage, confirmed by scans.I am 18 years old or older.You have had an allergic reaction to cisplatin or similar medicines in the past.I am fully active or can carry out light work.I have not had IV chemotherapy in the last 30 days.My study lesion has been treated with radiation before.You need to have a chest CT scan taken within one month before the screening visit.I have another cancer type, but it won't affect this trial's treatment.
- Group 1: Intratumoral Cisplatin Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned cis-diamminedichloroplatinum for use in treatments?
"Because cis-diamminedichloroplatinum is only in its first clinical trial, there has been limited data collected on safety and efficacy. For this reason, our team at Power rated the drug's safety a 1."
Is entrance to this experiment available for participants at the moment?
"The clinicaltrials.gov page for this research trial verifies that recruitment is currently ongoing. It was initially published on the 8th of March 2021, and last revised on May 20th 2022."
To what extent has enrollment for this trial been successful?
"Affirmative. Data present on clinicaltrials.gov proves that this medical trial, which was initially presented on March 8th 2021, is currently enlisting patients. 10 individuals are being admitted across a single site."
Has cis-diamminedichloroplatinum been tested in any other scientific trials?
"Currently, there are 689 active clinical trials conducted on cis-diamminedichloroplatinum with 274 of those being Phase 3 studies. Of these trial sites, the vast majority are located in Shanghai; however, 43222 locations internationally have taken up research into this drug."
To what afflictions does cis-diamminedichloroplatinum provide a remedy?
"Cis-diamminedichloroplatinum can be administered to treat advanced ovarian cancer, testicular cancer that is unresponsive to traditional treatments, and other forms of refractory malignancies."
Share this study with friends
Copy Link
Messenger